The latest price target for Maze Therapeutics (NASDAQ:MAZE) was reported by Guggenheim on February 25, 2025. The analyst firm set a price target for $19.00 expecting MAZE to rise to within 12 months (a possible 62.39% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Maze Therapeutics (NASDAQ:MAZE) was provided by Guggenheim, and Maze Therapeutics initiated their buy rating.

There is no last upgrade for Maze Therapeutics

There is no last downgrade for Maze Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maze Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maze Therapeutics was filed on February 25, 2025 so you should expect the next rating to be made available sometime around February 25, 2026.

While ratings are subjective and will change, the latest Maze Therapeutics (MAZE) rating was a initiated with a price target of $0.00 to $19.00. The current price Maze Therapeutics (MAZE) is trading at is $11.70, which is within the analyst’s predicted range.